| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 46,947 | 46,456 | ||
| Accounts receivable | 62,610 | 21,115 | ||
| Inventories, net | 109,378 | 134,228 | ||
| Prepaid expenses and other current assets | 54,221 | 47,774 | ||
| Total current assets | 273,156 | 249,573 | ||
| Property and equipment, net | 169,608 | 175,985 | ||
| Intangible assets, net | 725,000 | 725,000 | ||
| Total assets | 1,167,764 | 1,150,558 | ||
| Accounts payable | 459,652 | 568,799 | ||
| Accounts payable - related parties | 393,772 | 332,373 | ||
| Accrued expenses | 380,599 | 405,495 | ||
| Accrued interest - related party | 530,511 | 495,676 | ||
| Notes payable and loans (including 522,500 in default) | 1,044,827 | 970,117 | ||
| Notes payable and loans - related parties | 1,028,697 | 1,027,885 | ||
| Deferred revenue | 95,773 | 125,174 | ||
| Total current liabilities | 3,933,831 | 3,925,519 | ||
| Royalty liability | 700,000 | 700,000 | ||
| Notes payable and loans, net of current | 181,069 | 179,747 | ||
| Total liabilities | 4,814,900 | 4,805,266 | ||
| Common stock, 0.001 par value 1,500,000,000 shares authorized 961,992,601 issued and outstanding as of september 30, 2025 and 956,994,100 as of december 31, 2024 | 961,993 | 961,156 | ||
| Series a preferred stock, non-dividend, 2,500 votes per share, 0.001 par value, 50,000,000 authorized issued and outstanding 3,800-Series APreferred Stock | 4 | 4 | ||
| Additional paid-in capital | 31,488,626 | 31,408,548 | ||
| Accumulated other comprehensive income (loss) | - | -7,222 | ||
| Common stock issuable, 1,936,000 shares at december 31, 2024 | 0 | 0 | ||
| Accumulated deficit | -36,097,759 | -36,017,194 | ||
| Total stockholders' deficit | -3,647,136 | -3,654,708 | ||
| Total liabilities and stockholders' deficit | 1,167,764 | 1,150,558 | ||
BIOREGENX, INC. (BRGX)
BIOREGENX, INC. (BRGX)